4 stocks getting crushed by the market today

Investors rush for the exit in these four stocks

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P / All Ordinaries Index (Index: ^AORD) (ASX: XAO) looks headed to break a four day losing streak, rising 0.4% in late-afternoon trading.

But a number of stocks are on the nose with investors today. Here we take a look at the plummeting share prices of four stocks…

Stavely Minerals Ltd (ASX: SVY) has crashed down 32% to 32 cents. The management team at resources explorer Stavely were formerly Integra Mining execs – before the company was acquired by gold miner Silver Lake Resources Ltd (ASX: SLR). Late last month, Stavely announced what appeared to be positive results from its drilling program at the Stavely Porphyry copper project in Victoria. Evidently, some investors, having digested the report were less than impressed, and sold up.

Thundelarra Ltd (ASX: THX) shares have lost 28% to 15.5 cents. Another junior resources company, Thundelarra is exploring for copper, gold and uranium in Australia. Yesterday the company released some drilling results from its Red Bore project in Western Australia. Clearly investors found nothing to like about the results and like Stavely above, sold down shares in the company.

Toro Energy Limited (ASX: TOE) shares have dropped more than 19% to 10.5 cents. Earlier today, Rum Jungle Resources Ltd (ASX: RUM) announced that it had earned 51% of potash rights in a number of exploration tenements owned by Toro Energy. Seems Toro may have missed out, although Rum Jungle shares were also lower.

Prana Biotechnology Limited (ASX: PBT) has seen its shares fall 12.1% to trade at 25.5 cents. Shares in the small biotech stock spiked on Friday September 5, after the company announced it had received 'orphan drug designation' from the US Food and Drug Administration (FDA), for its PBT2 drug, which is used to treat Huntington disease. Investors may feel that the news wasn't as good as initially thought. Prana shares have lost more than 66% of their value since the beginning of this year.

Investing in speculative small cap stocks like most of these means a wild ride for investors – with no guarantee of a high return in comparison to the high risks.

Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »